Cancer care treats the tumour. Someone has to treat the fear.

Onco-Anxiology is the clinical study and treatment of anxiety in cancer patients across the full cancer journey. This page sets out what the field is, the six phases it maps, the chapters and research behind it, and free education material you can put in a patient's hands this week.

Research papers Request the book

01 — The field

What Onco-Anxiology is, and why it needs its own name.

Onco-Anxiology is an emerging area of clinical study and treatment of anxiety across the full cancer journey — from the first suspicion, through diagnosis and treatment, into survivorship, and to the end of life. It names anxiety specifically, as distinct from depression, adjustment disorder or general distress.

A patient with hypervigilance, anticipatory dread and a racing heart needs a different response from one with low mood and withdrawal. Naming them separately is the first step toward treating them correctly.

The field begins not at diagnosis, but at the moment the mind first grasps that there is a possibility of cancer. Someone finds a lump on a Tuesday, books an appointment, cancels it, rebooks it. By the time they reach the waiting room they have been afraid every day for three weeks — and they are not yet a patient.

Cancer care runs on a sequence of decisions, and every decision produces a wait. The diagnostic interval before a biopsy result. The days before a scan is read. The week treatment ends and the appointments stop. Clinically these are quiet periods — nothing is being done. For the patient they are the loudest part of the illness.

Onco-Anxiology vs psycho-oncology

Psycho-oncology opened the whole psychological dimension of cancer care. Onco-Anxiology narrows the lens to anxiety — its biology, its measurement, its treatment — and sets clinical standards for it.

Anxiety vs fear vs distress

Fear has an object: the biopsy happening now. Anxiety expects threat without a target and persists when nothing is happening. Distress is the umbrella term; it is not a diagnosis.

Anxiety vs appropriate concern

The question is not whether the fear makes sense. It is whether the fear is stopping someone from sleeping, attending appointments, or being present in their life.

The biology behind anxiety in cancer patients

Onco-Anxiology explains cancer-related anxiety through interconnected neurobiological pathways, including HPA-axis activation, amygdala sensitisation, prefrontal suppression during acute stress, and neuroinflammation from cytokines crossing the blood–brain barrier during chemotherapy and radiation.

Six phases. Six distinct expressions of cancer anxiety.

Cancer anxiety is not static—it evolves throughout the cancer journey. At every phase, its triggers, manifestations, and needs can change, requiring tailored assessment and phase-specific intervention.

Phase 01- Pre-diagnosis anxiety

The diagnostic interval — symptom to answer — is where screening avoidance, health anxiety and shame keep people out of clinics. Genetic high-risk populations live here permanently.

Phase 02- Anxiety at diagnosis

Acute stress suppresses the prefrontal cortex, so patients retain almost nothing said in the consultation. Structured disclosure, written summaries and a planned follow-up call do the real information transfer.

Phase 03- Treatment-phase anxiety

Anticipatory nausea, needle and port fear, claustrophobia in radiation masks, and the cumulative dread of cycle days. Procedural anxiety that threatens adherence is a clinical priority, not a comfort issue.

Phase 04- Scanxiety & recurrence fear

Anxiety rises days before imaging and spikes in the reporting gap. Fear of recurrence then persists for years, maintained by a safety-seeking loop in which reassurance briefly relieves and durably reinforces.

Phase 05- Post-treatment anxiety

The treatment-completion paradox: the appointments stop, the safety net feels removed, and anxiety rises exactly when everyone else expects relief. The highest-risk window sits around six weeks post-treatment.

Phase 06- End-of-life & existential dread

Fear of dependence, of pain, of being forgotten. Meaning-centred and dignity-based approaches address what symptom control alone cannot. Apparent acceptance frequently masks existential terror.

Where it attaches in cancer treatment

Onco-anxiology sits alongside medical, surgical and radiation oncology rather than after them. Each modality carries a characteristic anxiety, and knowing which one to expect is half the assessment.

Cancer Treatment Modalities & Burden	What It Does	Typical Setting	Anxiety It Commonly Produces
Surgery	Removes tumour and assesses local spread	Single admission, planned date	Pre-operative fear; waiting for the histopathology report
Chemotherapy	Cytotoxic drugs acting on dividing cells	Cycles over weeks to months	Anticipatory nausea, needle and port fear, cycle-day dread
Radiation therapy	Targeted ionising radiation	Daily fractions over several weeks	Claustrophobia, mask distress, fatigue-linked low mood
Targeted therapy	Blocks specific molecular drivers	Oral or infused, often long term	Resistance worry, dependence on a single drug working
Immunotherapy	Enables the immune system to attack tumour cells	Infusions, variable duration	Uncertainty about response; unfamiliar toxicity patterns
Hormonal therapy	Removes or blocks hormone signalling	Oral, often five years or more	Long-horizon adherence strain; daily reminder of the illness
Stem cell transplant	Replaces marrow after high-dose therapy	Prolonged inpatient stay, isolation	Isolation distress; fear of graft failure and relapse
Supportive & palliative care	Controls symptoms and supports function	Alongside all of the above	Often reduces anxiety — when introduced early and framed correctly

This table is a teaching aid, not a treatment protocol. Modality choice always follows tumour type, stage, biology and the individual patient's fitness and preference — the anxiety column describes what to screen for, not what to expect in every case.

02 — Key chapters explained

Eight chapters that change what happens in the clinic.

Onco-Anxiology runs to 28 chapters across seven parts. These eight carry the most immediate clinical weight — each one summarised here in the form a busy oncology team can actually use.

CHAPTER 01 · PART I

What is onco-anxiology?

Defines the field at the crossroads of oncology and mental health. Separates anxiety from fear, from distress, and from appropriate concern — because a patient with hypervigilance and a racing heart needs a different response from one with low mood and withdrawal.

The test is not whether the fear is reasonable. It is whether the fear is interfering with sleep, treatment or life.

CHAPTER 02 · PART I

The biology of cancer anxiety

HPA-axis activation, amygdala sensitisation, prefrontal suppression during acute stress, and neuroinflammation from cytokines crossing the blood–brain barrier during treatment. Anxiety here is measurable physiology, not a character trait.

Telling a patient their alarm system is working correctly — but cannot switch off — changes how they hear the diagnosis.

CHAPTER 05 · PART II

Anxiety at diagnosis

Acute stress suppresses the prefrontal cortex, so patients retain almost nothing said in the consultation. Chapter 5 covers structured disclosure, written summaries, and the follow-up call that does the real information transfer.

Assume the first consultation was not heard. Plan the second one accordingly.

CHAPTER 07 · PART II

Scanxiety and recurrence fear

Anxiety that rises days before imaging and spikes in the reporting gap, and the fear of recurrence that persists for years afterwards. Covers the safety-seeking loop in which reassurance briefly relieves and durably maintains the fear.

Shortening the scan-to-result gap is a psychological intervention, and one of the cheapest available.

CHAPTER 10 · PART III

Screening tools and clinical interviews

Distress Thermometer, GAD-7, HADS, FCRI-Severity and PHQ-9 — what each measures, how long it takes, and where it belongs in the pathway. Includes the referral routes that make a positive screen mean something.

Screening without a defined pathway for positive results is documentation, not care.

CHAPTER 11 · PART III

Differential diagnosis

Before anxiety is treated as anxiety, rule out corticosteroid agitation, akathisia from antiemetics, opioid toxicity or withdrawal, thyroid dysfunction, hypoxia, delirium and paraneoplastic syndromes.

Akathisia mistaken for anxiety is one of the most consequential missed diagnoses in oncology. Review the medication list first.

CHAPTER 13 · PART IV

Cognitive behavioural therapy in oncology

CBT adapted for medical reality, where the feared outcome is sometimes real. Behavioural experiments, graded exposure for needle and scanner phobia, and worry postponement rather than thought suppression.

Standard CBT scripts fail when the catastrophe is genuinely possible. The adaptation is the clinical skill.

CHAPTER 23 · PART VI

Caregiver and family anxiety

Caregivers frequently score as high as patients on anxiety measures and are almost never screened. Covers assessment of the family unit, role strain, and financial stress as an anxiety driver in its own right.

Ask about money. In many settings, financial strain is a larger anxiety driver than the prognosis.

Remaining Chapters & Annexes

The remaining chapters cover epidemiology, treatment-phase and survivorship anxiety, end-of-life and existential fear, ACT, mindfulness, meaning-centred and group therapies, anxiolytic prescribing, integrative modalities, paediatric and cross-cultural contexts, clinician burnout, service integration and digital delivery.

03 - Research Papers

The Evidence Behind Onco-Anxiology

The evidence base behind Onco-Anxiology explores the causes, mechanisms, assessment, and management of anxiety in cancer patients. Selected primary research is grouped by key questions, with systematic reviews and meta-analyses prioritised wherever available.

These studies provide insight into cancer anxiety across different stages of the cancer journey. A full reference list, organised by section, appears in the book.

Study	Design	Key finding
Mitchell AJ et al. - Lancet Oncology, 2011	Meta-analysis, 94 interview-based studies	Anxiety disorders present in a substantial minority of patients in oncological and haematological settings; roughly one in three develop clinical anxiety at some point.
Zabora J et al. - Psycho-Oncology, 2001	Cross-sectional, 4,496 patients	Distress prevalence varies markedly by tumour site, arguing for site-specific screening rather than a single threshold.
Linden W et al. - Journal of Affective Disorders, 2012	Cross-sectional, 10,153 patients	Anxiety exceeds depression in prevalence and is highest in younger patients and in women.

Study

Mitchell AJ et al. - Lancet Oncology, 2011

Design

Meta-analysis, 94 interview-based studies

Key finding

Anxiety disorders present in a substantial minority of patients in oncological and haematological settings; roughly one in three develop clinical anxiety at some point.

Study

Zabora J et al. - Psycho-Oncology, 2001

Design

Cross-sectional, 4,496 patients

Key finding

Distress prevalence varies markedly by tumour site, arguing for site-specific screening rather than a single threshold.

Study

Linden W et al. - Journal of Affective Disorders, 2012

Design

Cross-sectional, 10,153 patients

Key finding

Anxiety exceeds depression in prevalence and is highest in younger patients and in women.

Study	Design	Key finding
Kangas M et al. - Psychological Bulletin, 2002	Systematic review	Diagnosis and treatment function as traumatic stressors, with acute stress reactions clustering in the first weeks.
Brocken P et al. - Lung Cancer, 2012	Systematic review of diagnostic intervals	Longer waits for diagnostic certainty are associated with higher distress; rapid diagnostic pathways reduce it.

Study

Kangas M et al. - Psychological Bulletin, 2002

Design

Systematic review

Key finding

Diagnosis and treatment function as traumatic stressors, with acute stress reactions clustering in the first weeks.

Study

Brocken P et al. - Lung Cancer, 2012

Design

Systematic review of diagnostic intervals

Key finding

Longer waits for diagnostic certainty are associated with higher distress; rapid diagnostic pathways reduce it.

Study	Design	Key finding
Bauml JM et al. - JNCCN, 2016	Cross-sectional survey of scan-associated distress	Scan-associated distress is common and concentrated in the interval between imaging and result disclosure.
Simard S, Savard J - Supportive Care in Cancer, 2009	Instrument development and validation (FCRI)	Fear of cancer recurrence is measurable as a distinct multidimensional construct with a usable severity subscale.
Simard S et al. - Journal of Cancer Survivorship, 2013	Systematic review, 130 studies	Fear of recurrence persists for years after treatment and does not reliably decline with time alone.

Study

Bauml JM et al. - JNCCN, 2016

Design

Cross-sectional survey of scan-associated distress

Key finding

Scan-associated distress is common and concentrated in the interval between imaging and result disclosure.

Study

Simard S, Savard J - Supportive Care in Cancer, 2009

Design

Instrument development and validation (FCRI)

Key finding

Fear of cancer recurrence is measurable as a distinct multidimensional construct with a usable severity subscale.

Study

Simard S et al. - Journal of Cancer Survivorship, 2013

Design

Systematic review, 130 studies

Key finding

Fear of recurrence persists for years after treatment and does not reliably decline with time alone.

Study	Design	Key finding
Roth AJ et al. - Cancer, 1998	Validation study (Distress Thermometer)	A single-item visual scale performs adequately as a rapid first-pass screen.
Spitzer RL et al. - Archives of Internal Medicine, 2006	Validation study (GAD-7)	Seven items give a reliable severity measure for generalised anxiety in medical settings.
Zigmond AS, Snaith RP - Acta Psychiatrica Scandinavica, 1983	Instrument development (HADS)	Separating anxiety and depression subscales, with somatic items excluded, suits physically ill populations.

Study

Roth AJ et al. - Cancer, 1998

Design

Validation study (Distress Thermometer)

Key finding

A single-item visual scale performs adequately as a rapid first-pass screen.

Study

Spitzer RL et al. - Archives of Internal Medicine, 2006

Design

Validation study (GAD-7)

Key finding

Seven items give a reliable severity measure for generalised anxiety in medical settings.

Study

Zigmond AS, Snaith RP - Acta Psychiatrica Scandinavica, 1983

Design

Instrument development (HADS)

Key finding

Separating anxiety and depression subscales, with somatic items excluded, suits physically ill populations.

Study	Design	Key finding
Faller H et al. - Journal of Clinical Oncology, 2013	Meta-analysis of psycho-oncological interventions	Individual and group psychotherapy produce small-to-moderate, durable reductions in emotional distress.
Piet J, Würtzen H, Zachariae R - JCCP, 2012	Meta-analysis of mindfulness-based therapy	Mindfulness-based programmes reduce anxiety and depression in patients and survivors.
Breitbart W et al. - Journal of Clinical Oncology, 2015	Randomised controlled trial	Meaning-centred group psychotherapy improves spiritual wellbeing and reduces distress in advanced cancer.
Chochinov HM et al. - Lancet Oncology, 2011	Randomised controlled trial (dignity therapy)	A brief dignity-based intervention improves end-of-life experience on patient-reported measures.
Bradt J et al. - Cochrane Database, 2016	Cochrane systematic review, 52 trials	Music interventions reduce anxiety, pain and fatigue with no reported harms.

Study

Faller H et al. - Journal of Clinical Oncology, 2013

Design

Meta-analysis of psycho-oncological interventions

Key finding

Individual and group psychotherapy produce small-to-moderate, durable reductions in emotional distress.

Study

Piet J, Würtzen H, Zachariae R - JCCP, 2012

Design

Meta-analysis of mindfulness-based therapy

Key finding

Mindfulness-based programmes reduce anxiety and depression in patients and survivors.

Study

Breitbart W et al. - Journal of Clinical Oncology, 2015

Design

Randomised controlled trial

Key finding

Meaning-centred group psychotherapy improves spiritual wellbeing and reduces distress in advanced cancer.

Study

Chochinov HM et al. - Lancet Oncology, 2011

Design

Randomised controlled trial (dignity therapy)

Key finding

A brief dignity-based intervention improves end-of-life experience on patient-reported measures.

Study

Bradt J et al. - Cochrane Database, 2016

Design

Cochrane systematic review, 52 trials

Key finding

Music interventions reduce anxiety, pain and fatigue with no reported harms.

Study	Design	Key finding
Geng H-M et al. - Medicine, 2018	Meta-analysis of caregiver samples	Family caregivers show anxiety prevalence comparable to patients, yet are rarely screened in routine care.

Study

Geng H-M et al. - Medicine, 2018

Design

Meta-analysis of caregiver samples

Key finding

Family caregivers show anxiety prevalence comparable to patients, yet are rarely screened in routine care.

04 — Patient Education

Understanding cancer anxiety through Onco-Anxiology

Eight practical handouts designed to help patients and families understand and manage cancer anxiety at different stages of the cancer journey. Written in plain language, without unnecessary jargon, each handout is short enough to read in a waiting room and practical enough to act on.

Handout 01

What is cancer anxiety?

For any patient, at any stage. Names the experience, explains how common it is, and makes clear it is treatable.

Handout 02

Why your body feels this way

The biology in simple terms — cortisol, the amygdala, the alarm that works correctly but will not switch off.

Handout 03

Before the scan

Managing scanxiety in the days before imaging and the gap before the result arrives.

Handout 04

When treatment ends

For the drop that follows the last session — when the appointments stop and the safety net feels removed.

Handout 05

Fear of cancer coming back

For survivorship. Why reassurance stops working, and what helps instead.

Handout 06

Breathing and music for anxiety

Two tools that need no appointment, no prescription and no equipment. Usable at 3 a.m.

Handout 07

A guide for caregivers and families

For the people carrying it alongside the patient — and usually never asked how they are.

Handout 08

When to ask for more help

Clear thresholds, and the exact words to use when raising it with a clinical team.

If you are the patient

Feeling frightened after a cancer diagnosis is a normal response to an abnormal situation. It is not a weakness, and it is not a sign that you are coping badly. The question worth asking is not whether your fear makes sense — it almost certainly does — but whether it is getting in the way of your sleep, your treatment, your relationships or your day.

When it starts interfering with those things, it has crossed into something that deserves treatment. Say so to your team. Clinical teams expect this conversation, and patients who raise it tend to receive better care overall.

If you are the caregiver

You may worry that suggesting psychological support implies something is seriously wrong. It does not. It means taking the anxiety as seriously as the tumour — which is what good cancer care already does.

Your own anxiety is also real and also measurable. Caregivers often score as high as patients on anxiety scales and are rarely screened for it. Handout 7 is written for you, not about you.

05 — REQUEST THE BOOK

Tell us where you work. We will send the right edition.

Two editions are available. Clinicians and departments receive the full clinical text with screening instruments and case studies. Patients, families and caregivers receive the education edition — the eight handouts, in plain language, with nothing to buy.